-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Reducing the frequency of insulin injections can help improve the treatment compliance of people with type 2 diabetes, icodec, a long-acting form of insulin that can be given once a week to treat diabetes.
researchers recently conducted a 26-week randomized, double-blind, Phase II trial with insulin glycerion U100 as a control to see the effectiveness and safety of insulin icodec once a week.
Patients with type 2 diabetes who had not previously received long-term insulin therapy were involved in the study, with poor blood sugar control, 7.0% to 9.5% of glycified hemoglobin levels, and previously treated with metformin, using or not using dipeptide peptide enzyme 4 inhibitors.
end of the study was a change in glycation hemoglobin levels from baseline examination to week 26.
safe endpoints, including adverse events related to hypoglycemia and insulin.
247 patients were studied with similar baseline characteristics between groups, with an average baseline glycation hemoglobin level of 8.09 percent in the icodec group and 7.96 percent in the insulin insulin glycerin group.
, at 26 weeks, icodec levels of glycoglobin changed by -1.33% compared to the baseline, compared with -1.15% in the glycine group and 6.69% and 6.87% on average.
week 26, the difference between groups was -0.18% compared to the baseline. The occurrence of hypoglycemia between
groups with a severity of 2 levels (blood sugar levels of 54 mg/dL) or 3 levels (severe cognitive impairment) was similar and low: 0.53 events/patient years in the icodec group and 0.46 events/patient-years in the insulin group with a risk ratio of 1.09.
the differences of insulin-related adverse events between the two groups were not significant, and the rate of hypersensitivity reaction and injection site reaction was low.
most adverse events are mild and there are no serious adverse events associated with experimental drugs.
study found that for people with type 2 diabetes, icodec insulin treatment once a week had a similar sugar-lowering effect and safety to insulin glycelin U100.
。